Aptinyx Inc is a clinical-stage biopharmaceutical company developing synthetic small molecules, including NYX-2925 and NYX-783, for the treatment of chronic pain and post-traumatic stress disorder. NYX-2925 functions as an NMDA receptor modulator to enhance synaptic plasticity, targeting the underlying mechanisms of chronic pain.
Funding
$267.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Many brain and nervous system disorders lack effective treatments due to the complex nature of neural cell communication. Traditional approaches targeting NMDA receptors have been limited by issues of over-activation or full inhibition, leading to toxicity or significant side effects.
Solution
Aptinyx is a biopharmaceutical company developing therapies for disorders of the brain and nervous system, utilizing a unique platform that modulates NMDA receptors to enhance synaptic plasticity without causing over-activation or inhibition. Their compounds bind to a unique domain on the NMDA receptor, resulting in optimal modulation and a favorable safety profile. This approach aims to restore normal balance in the brain and CNS, offering a potential paradigm shift in treating various neurological and neuropsychiatric conditions. Aptinyx is advancing development candidates across post-traumatic stress disorder, cognitive impairment, and opioid use disorder.
Target Audience
The primary target audience includes individuals suffering from neurological and neuropsychiatric disorders such as post-traumatic stress disorder, cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies, and opioid use disorder.
Features
- Novel medicinal chemistry platform for discovering NMDA receptor modulators
- Compounds modulate NMDA receptors to enhance synaptic plasticity
- Avoids caustic effects associated with over-activation or full inhibition of NMDA receptors
- NYX-783: Oral small molecule in development for PTSD and opioid use disorder; has Fast Track designation by the FDA for the treatment of PTSD
- NYX-458: Oral small molecule in development for cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies
- Clinical programs span cognitive impairment, post-traumatic stress disorder, and opioid use disorder